Label-free microscopic assessment of glioblastoma biopsy specimens prior to biobanking

*Joseph Georges, B.S.,1,6 Aqib Zehri, B.S.,1,7 Elizabeth Carlson, B.S.,5 Joshua Nichols, B.A.,1 Michael A. Mooney, M.D.,2 Nikolay L. Martirosyan, M.D.,1,8 Layla Ghaffari,5 M. Yashar S. Kalani, M.D., Ph.D.,2 Jennifer Eschbacher, M.D.,3 Burt Feuerstein, M.D., Ph.D.,7 Trent Anderson, Ph.D.,1 Mark C. Preul, M.D.,1 Kendall Van Keuren-Jensen, Ph.D.,8 and Peter Nakaji, M.D.2

1Neurosurgery Research Laboratory, 2Division of Neurological Surgery, and 3Division of Neuropathology, Barrow Neurological Institute, St. Joseph’s Hospital and Medical Center, Phoenix; 4Department of Basic Medical Sciences, The University of Arizona College of Medicine, Phoenix; 5Neurogenomics Division, Translational Genomics Research Institute, Phoenix; 6School of Life Sciences, Arizona State University, Tempe; 7College of Medicine, The University of Arizona, Phoenix; and 8Division of Neurosurgery, Department of Surgery, The University of Arizona, Tucson, Arizona

Glioblastoma is the most common primary brain tumor with a median 12- to 15-month patient survival. Improving patient survival involves better understanding the biological mechanisms of glioblastoma tumorigenesis and seeking targeted molecular therapies. Central to furthering these advances is the collection and storage of surgical biopsies (biobanking) for research. This paper addresses an imaging modality, confocal reflectance microscopy (CRM), for safely screening glioblastoma biopsy samples prior to biobanking to increase the quality of tissue provided for research and clinical trials. These data indicate that CRM can immediately identify cellularity of tissue biopsies from animal models of glioblastoma. When screening fresh human biopsy samples, CRM can differentiate a cellular glioblastoma biopsy from a necrotic biopsy without altering DNA, RNA, or protein expression of sampled tissue. These data illustrate CRM’s potential for rapidly and safely screening clinical biopsy samples prior to biobanking, which demonstrates its potential as an effective screening technique that can improve the quality of tissue biobanked for patients with glioblastoma.

(http://thejns.org/doi/abs/10.3171/2013.11.FOCUS13478)

Key Words • glioblastoma • confocal reflectance microscopy • biobank • biopsy

Each year, more than 22,000 Americans are diagnosed with high-grade gliomas. More than half of these brain tumors are glioblastomas, the most aggressive and essentially noncurable form of this disease.3 Standard treatment for newly diagnosed glioblastoma is resection followed by ionizing radiation and chemotherapy.11 However, current therapeutic approaches provide minimal survival benefit, with median survival remaining formidable at 12 months and 2-year survival remaining less than 30%.8,16

A key component to improving patient survival involves a better understanding of the biological mechanisms in tumor formation and seeking targeted molecular therapies.13 With recent advances in medical genetics, computational biology, and biotechnology, novel molecular approaches such as immunotherapy, vaccine therapy, and gene therapy are being extensively explored in treating brain tumors. Furthering these advances requires collecting surgical biopsy specimens (biobanking) to study gliomagenesis and to assess a patient’s eligibility for potentially life-prolonging clinical trials. Unfortunately, due to the necrotic features of malignant gliomas and our inability to assess tissue prior to biobanking, a large portion of biobanked glioblastoma samples lack appropriate cellularity to be used in these two research arenas. A method for safely screening tissue biopsies prior to biobanking is needed to increase the quality of tissue provided for research and clinical trials.

Confocal reflectance microscopy (CRM) is an optical imaging modality that can rapidly assess tissue without physical manipulation or application of exogenous contrast agents.1,17 In CRM, a laser is raster-scanned across a specimen without generating a detectable Stokes shift. Photons from the laser are scattered back toward
the objective and passed through a confocal aperture. This allows multiple optical sections to be collected from a sample without physical sectioning. When applied to thick tissue samples, CRM can identify individual cells and structural components within the tissue.1 Compared with other optical sectioning techniques such as fluorescence confocal microscopy, structured illumination, or nonlinear microscopy, CRM introduces a fraction of the energy into tissue samples that is encountered with these other techniques. Thus, CRM is theoretically less likely to alter tissue characteristics by generation of free radicals or thermal energy.

We hypothesize that CRM will provide a safe and rapid means for screening glioblastoma tissue prior to biobanking. In this study we used CRM to assess tissue cellularity from rodent glioma models, and subsequently evaluated the molecular integrity of tissue imaged with CRM. Lastly, we assessed CRM on clinical samples with a pathology-based CRM system. Our data illustrate CRM’s potential for screening clinical biopsy samples prior to biobanking, which can augment information gained from resected tissue for molecular and translational research and for determining the eligibility of patients with glioblastoma for enrollment into clinical trials. Although numerous applications for intraoperative CRM exist, the goal of this study is to determine its efficacy as a rapid screening technique that will improve the quality of tissues collected and biobanked for glioblastoma research.

Methods

Intracranial Implantation

Nude rats were acquired from Charles River Laboratories. Five rats were anesthetized by intramuscular injection of a mixture of 10 mg/kg xylazine and 80 mg/kg ketamine (Wyeth) and placed in a small animal stereotactic headframe (Model 900, David Kopf Instruments). A 10-mm incision was made starting between the animal’s eyes to expose bregma. A bur hole was made 3.5 mm lateral to bregma. Human glioma cells (U251; ATCC) were infused at a depth of 4.5 mm below the surface of the brain after the syringe (Hamilton) was advanced 5.0 mm to create a 0.5-mm pocket. The cell suspension was infused using a UMP3–1 UltraMicroPump microinjector (WPI) set to a volume of 10 μl with an infusion rate of 3.00 μl/min. The needle was withdrawn 2 minutes after the injection to minimize backflow of the cell suspension. The bur hole was covered with bone wax and the skin incision was sutured prior to the rats emerging from anesthesia. All animal procedures were performed according to principles outlined in the NIH Guide for the Care and Use of Laboratory Animals.

Rodent Tissue

Twenty-eight days after implantation, rodents with xenografts were deeply anesthetized using xylazine and ketamine (as described above), and whole brain specimens were collected. Coronal slices (350 μm thick) were cut from the cerebrum on a Leica VT1200 vibratome and placed in artificial CSF containing the following (in mM): 126 NaCl, 26 NaHCO₃, 2.5 KCl, 1.25 NaH₂PO₄, 2 MgSO₄, 2 CaCl₂ and 10 glucose, pH 7.4). Slices were then fixed in 4% paraformaldehyde at 4°C overnight and washed 3 times with phosphate-buffered saline. Three tumor-containing slices per animal were incubated with DAPI for 45 minutes at room temperature, rinsed 3 times with phosphate-buffered saline, and placed into no. 1.5 glass-bottom dishes (MatTek) for imaging. A coefficient of determination analysis was used to compare cells identified with CRM to cells labeled with DAPI.

The 2 rodents used for molecular experiments were deeply anesthetized using xylazine and ketamine and rapidly decapitated. Whole brains were placed in ice-cold artificial CSF and sectioned into 1-mm coronal sections using a rodent brain block. The cerebrum from each section was blocked into 4 equivalent sections. Two sections were immediately frozen in liquid nitrogen for reference. At 15, 30, 45, 60, 90, and 120 minutes, 2 sections were placed into glass-bottom dishes. At each time point, the cortex, corpus callosum, and caudate/putamen from 1 section was imaged with CRM. As a control, 1 section was simultaneously placed on the stage of the microscope but not imaged. Next, each section was frozen in liquid nitrogen for assessment of DNA, RNA, and protein.

Imaging

All samples were imaged in uncoated no. 1.5 glass-bottom dishes. Confocal reflectance microscopy was conducted with a Zeiss inverted 710 laser-scanning confocal microscope equipped with a x40/1.2 numerical aperture water immersion objective. For reflectance imaging, a 633-nm diode laser was raster scanned across the sample, and reflected photons were collected by tuning the emission filters to allow photons with the same wavelength of the incident laser passage to the photomultiplier tube. For DAPI imaging, samples were excited with a 405-nm diode laser and 430–490 nm emission was collected. The confocal aperture was set to 1 Airy unit for all imaging. The laser and gain values were set to fill the dynamic range of the photomultiplier tube, and the frame size was set to sample at Nyquist. Images were collected in 12-bit format absent of nonlinear processing.

DNA Isolation and Analysis

DNA was isolated from brain tissue using the QIAamp DNA Mini (Qiagen), per the manufacturer’s instructions. DNA was quantified using the Nanodrop Spectrophotometer (Thermo Scientific). Samples were loaded in equal concentrations (100 ng) in a 1% agarose gel with ethidium bromide and imaged on an Alpha Imager.

RNA Isolation and Analysis

Tissue was homogenized in 500 μl of Ambion’s Cell Disruption Buffer (Life Technologies) and subsequently isolated using Ambion’s mirVana Paris kit (Life Technologies), per the manufacturer’s instructions. RNA concentrations were determined using the Nanodrop Spectrophotometer (Thermo Scientific), which gave dilutions necessary to remain within the dynamic range of the Bioanalyzer. The integrity of the RNA was assessed using Agilent 2100 Bioanalyzer Nanochips (Agilent Technologies).
Western Blot Analysis

Frozen tissue was sectioned on dry ice and designated for protein, RNA, or DNA analysis. Protein lysate was made by placing brain sections into 750 μl of Ambion’s Cell Disruption Buffer (Life Technologies), triturated using RNase-free pipettes, and sonicated using Covaris Sonolab at 2%–5% for 5 seconds, 2%–20% for 15 seconds, 2%–20% for 15 seconds, and 2%–5% for 5 seconds (Covaris Inc).

Protein concentrations were quantified by bicinchoninic acid assay, and 18 μg/lane was loaded in 4%–12% Bis-Tris gels and run using NuPage electrophoresis reagents (Invitrogen). Protein was transferred onto Novex nitrocellulose membrane (Invitrogen) and thereafter incubated for 1 hour in a blocking solution consisting of 5% bovine serum albumin (Sigma Aldrich) in tris-buffered saline with 0.1% Tween (Thermo Fisher Scientific). Primary antibodies were incubated for 12 hours at 4°C while secondary horseradish peroxidase–conjugated antibodies were incubated for 1 hour at room temperature. Blots were probed for protein kinase B (Akt: 1:1000, Cell Signaling) and GAPDH (1:60,000, Millipore). Horseradish peroxidase–conjugated secondary antibodies were anti-rabbit (1:2000, Cell Signaling) and anti-chicken (Millipore).

Blots were developed using Pierce SuperSignal Chemiluminescent Substrate (Thermo Fisher Scientific) per the manufacturer’s instructions. Protein signal was detected on radiographic film (General Electric).

Statistical Analysis

A coefficient of correlation (R² value) was determined between DAPI-stained nuclei and nuclei detected by CRM using Graphpad Prism. Differences were considered statistically significant for probability < 0.05. The Agilent 2100 Bioanalyzer provided an RNA integrity number (RIN), calculated algorithmically by including the 28s/18s (ribosomal subunit) ribosomal RNA bands, the region before the peaks, signal areas, and intensities. An elevated threshold baseline and a decreased 28s/18s ratio are both indicative of RNA degradation, while high 28s and 18s ribosomal RNA peaks as well as a small amount of 5s RNA or an RNA number greater than 7.5 are indicative of intact RNA. Image J was used to determine density (intensity) of bands on a Western blot. Data analysis consisted of determining relative density. Results were expressed as means and mean square error (SEM) data with normal distribution that were compared by 1-way ANOVA and a Student t-test.

Clinical Samples

The clinical research was approved by the Institutional Review Board of St. Joseph’s Hospital and Medical Center and Barrow Neurological Institute, where all surgery was performed. Preoperatively, patients signed an informed consent form for participation. Samples (mean size 4 mm × 2 mm × 2 mm) were obtained at the time of craniotomy from within the tumor mass at a location determined to be safe by the surgeon. Tissue samples were placed in ice-cold artificial CSF and transported from the operating room to the pathology-based CRM system. There, the samples were immediately placed in no. 1.5 glass-bottom dishes and imaged. Investigators conducting imaging experiments were unaware of the pathological diagnosis at the time of imaging. Final diagnosis was determined by traditional immunohistochemical analysis and paraffin-embedded H & E staining of the sampled tissue. For the purpose of comparisons, the histopathological diagnosis made by a board-certified neuropathologist (J.E.) was accepted as the final diagnosis.

Results

Differentiating Neoplastic Cellular Tumor From Acellular Tissue

To investigate the potential of reflectance imaging to identify tissue cellularity, we first imaged normal rat brain. We found that CRM adequately contrasted normal brain cytoarchitecture, such as cell bodies and axons, as well as blood vessels (Fig. 1). This prompted us to test the utility of CRM to differentiate cellular and acellular tumor biopsy regions by imaging acute slices generated from rodent glioblastoma xenografts. We incubated slices with DAPI to label all cell nuclei and we subsequently imaged the slices with CRM and laser-scanning confocal microscopy (n = 15 slices from 5 animals). We collected 5 images per acute slice and compared cells identified with CRM to cells identified with DAPI. We found CRM provided definitive contrast between cell nuclei, cytoplasm, and extracellular tissue. Within tumor regions, CRM provided contrast to visualize hypercellular tumor regions (Fig. 2A–C) and relatively acellular peritumoral regions with isolated cell populations (Fig. 2E–G). In hypercellular tissue (r² = 0.97) and acellular regions (r² = 0.098) we found CRM contrast strongly correlated with cells labeled with DAPI (Fig. 2D and H).

Effect of CRM on the Molecular Characteristics of Examined Tissue

To determine if CRM alters the molecular characteristics of tissue, we compared DNA, RNA, and protein from tissue imaged with CRM to tissue immediately frozen for analysis and tissue that had reflectance imaging and was left out for varying amounts of time. Although the typical time from resection to reception in pathology and assessment using CRM typically takes 15 minutes, we tested for as long as 180 minutes postresection. Neoplastic tissues are heterogeneous in terms of cellularity and gene and protein expression and may yield interspecimen molecular variability. Therefore, we conducted these experiments on control tissue harvested from rodent normal brain.

DNA quality was assessed in CRM-imaged samples, which showed no differences compared with immediately frozen controls. Discrete DNA bands were detectable up to 180 minutes after extraction (Fig. 3B), suggesting no degradation of DNA elements. An RIN was generated to determine the integrity of isolated RNA. An RIN of 1 suggests strong degradation while an RIN greater than 8 suggest minimal degradation. The RIN was comparably the same between control and CRM-imaged groups (Fig.
3C), indicating no effect of CRM on RNA integrity of imaged samples. RNA integrity remained relatively the same up to 120 minutes after biopsy. There was a slight decrease after 120 minutes after biopsy in RIN value that was similar for both the control and CRM tissue, likely due to RNases within the tissue over time. Protein kinase B, a protein involved in glioblastoma pathogenesis, was examined for potential damage after imaging with CRM.

![Reflectance and DAPI images of rodent xenograft tumor region](image1)

**Fig. 1.** Acute slices of normal rat brain from the cortex (left) and ventricle and corpus callosum (right) shown using contrast-free reflectance imaging. **Left:** Confocal reflectance microscopy contrasts cell bodies, axons, and blood vessels in normal rat brain. Cell bodies appear as multiple hypointense circular regions within the tissue. Note the typical lack of cell bodies contrasted in Layer 1 of the cortex. Myelinated axons are visualized as hyperintense fibers extending from cell bodies. **Right:** White matter tracts in the corpus callosum generate a hyperintense reflectance signal. Individual cell bodies are contrasted in the choroid plexus. A lack of signal is appreciated from the fluid-filled ventricle. Bar = 20 μm.

**Fig. 2.** Confocal reflectance imaging identifies cellular tumor in rodent acute slices. **A:** Reflectance image of rodent xenograft tumor region; note hypointense cell nuclei. **B:** DAPI stain of identical tumor region identifies all cells in the field of view. **C:** Merged image shows location of cells contrasted by reflectance in comparison with cells labeled with DAPI. Bar = 20 μm. **D:** Plot of coefficient of determination and 95% CIs for tumor cells identified by reflectance imaging ($r^2 = 0.97$). The solid line is the best fit slope. The dotted lines mark the 95% CIs. The dots are the counts from each region of interest. The y axis is actual number of cells (per DAPI staining), and the x axis shows cells counted by reflectance imaging. **E:** Reflectance image of cellular tumor and adjacent acellular region from rodent xenograft; note isolated cell populations. **F:** Fluorescence confocal image of identical region labeled with DAPI. **G:** Merged image of reflectance and fluorescence images from tumor and peritumoral tissue interface. **H:** Plot of coefficient of determination and 95% CIs for cells identified by reflectance imaging at tumor and acellular tissue interface ($r^2 = 0.98$). Bar = 20 μm.
Confocal reflectance microscopy assessment of glioblastoma

Western blot analysis of extracted tissue showed that up to 120 minutes after extraction, discrete Akt bands were detectable and contained similar density to control samples (Fig. 3D).

**Differentiating Human Cellular From Acellular Brain Tumor Biopsies**

To test the ability of CRM to differentiate cellular tumor from acellular tissue samples in a clinical setting, we imaged 2 fresh human brain tumor biopsy specimens: 1 yielding radiation necrosis tissue and 1 with known glioblastoma cellular tissue. Tissue samples were placed in ice-cold artificial CSF and imaged with CRM. Imaging time per sample was less than 2 minutes. Samples were then compared with final histopathological diagnosis.

Similar to our findings in rodent xenografts, we found that CRM contrasted cellular regions from acellular regions in human biopsy samples. Tissue samples identified as cellular with CRM were found to be cellular with subsequent histopathological assessment (Fig. 4A and C). Confocal reflectance microscopy correctly identified acellular regions in necrotic tissue samples (Fig. 4B and D).

**Discussion**

Our data illustrate the utility of CRM as a safe and rapid technique for identifying the cellularity of glioma tissue prior to biobanking. This imaging modality can be immediately used on fresh tissue samples without application of exogenous contrast agents and without altering the molecular characteristics of examined tissue. Confocal reflectance microscopy can provide a much-needed tool for neurosurgery and neuropathology teams by maximizing the quality of tissue samples collected during resection. Although other imaging modalities may provide excellent images, their greater energy and the possible...
need to use exogenous fluorophores could affect future molecular analysis of the tissues.\(^\text{12}\)

We found CRM did not alter the DNA, RNA, or protein that could be extracted and quantified from tissue biopsy specimens screened up to 2 hours after resection. Confocal reflectance microscopy images collected from these samples could be digitally stored and potentially recalled with biobanked specimens. This metadata could prove advantageous to researchers who want more information about tumor morphology or cellularity before they choose it for laborious or costly analyses.

Confocal reflectance microscopy provides cellular and subcellular information. We ascertain CRM to have diagnostic utility, as many images in this study revealed distinct morphological details of glioblastoma such as cellularity, vasculature, and necrosis (Figs. 1, 2, 3A, and 4) typically identified with traditional histopathological H & E staining.

Many translational neurooncology studies rely on human glioblastoma tissue samples that appropriately represent an original tumor. Unintentional utilization of necrotic or nonrepresentative tissue samples can lead to erroneous and biased results that confound molecular and genetic experiments. In studies that advance to clinical trials, patient biopsies are often screened to determine eligibility for a targeted clinical trial. Utilization of CRM can ensure that patients are not mistakenly excluded from these trials after standard therapy has failed. Therefore, screening for high-quality tissue specimens with CRM can facilitate the advancement of our knowledge of glioma biology and can ensure qualified patients receive potential life-prolonging therapies and can enroll in appropriate clinical trials.\(^\text{14}\)

Current limitations of CRM include limited imaging depth penetration. With our imaging parameters, CRM could assess tissue from the surface to a depth of 200–300 μm. However, we did not find that this depth limitation altered our assessment of tissues in our study. At present, few pathology departments contain the imaging hardware or personnel required to screen tissue biopsies with CRM. We have a full-scale laboratory Zeiss LSM710 microscope located for research purposes in the hospital’s clinical pathology department where operating room specimens are routinely received, but equivalent equipment is rarely found in the pathology departments of most hospitals. However, modernization of pathology departments may include addition of confocal microscopes and other systems capable of CRM that will allow the screening of samples within 2 hours. Lastly, ex vivo CRM is limited by the ability to only assess tissue that is intraoperatively selected to represent tumor. A handheld intraoperative CRM device could potentially overcome sampling error and allow assessment of tissue samples prior to resection.

Past studies have shown the utility of CRM technology in providing cellular and subcellular detail, specifi-
Confocal reflectance microscopy assessment of glioblastoma

cally in diagnosing dermatological conditions, identifying neoplastic tissue and margins, and assessing diseased and normal liver tissue.1,2,4–6,8,10,15,18 Our study is the first to assess human brain tumor tissue purely with CRM. By quantifying DNA, RNA, and protein, we also demonstrate the first time the ability of CRM to preserve the molecular integrity of tissue biopsies.

Conclusions

Confocal reflectance microscopy can screen brain tumor tissue cellularity for inclusion into biobanks while preserving molecular integrity of tissue samples. Confocal reflectance microscopy provides a rapid imaging modality that can accurately provide ex vivo morphological information in animal models and fresh human biopsies. In comparison with traditional histopathological methods, this technique does not rely on exogenous dyes or fixation and sectioning. Furthermore, this technique preserves the DNA, RNA, and protein characteristics of tissues, allowing further analysis of imaged specimens. Future technical developments of CRM include utilization of a handheld confocal endomicroscope for imaging, which would allow rapid and safe histopathological assessments in vivo. Further applications of CRM may include rapid ex vivo and in vivo examination of brain tumors in addition to glioblastoma. This technique ensures that high-quality specimens are biobanked for future molecular studies of tumor samples and for assessing patient eligibility for clinical trials based on tumor characteristics.

Disclosure

The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

Author contributions to the study and manuscript preparation include the following: Conception and design: Nakaji, Georges, Zehri, Eschbacher, Feuerstein, Preul, Keuren-Jensen. Acquisition of data: Georges, Zehri, Carlson, Nichols, Martirosyan, Ghaffari, Eschbacher, Anderson, Keuren-Jensen. Analysis and interpretation of data: Georges, Zehri, Carlson, Ghaffari, Eschbacher, Keuren-Jensen. Drafting the article: Georges, Zehri. Critically revising the article: Nakaji, Mooney, Kalani, Eschbacher, Feuerstein, Preul, Keuren-Jensen. Administrative/technical/material support: Nakaji, Peull, Keuren-Jensen. Statistical analysis: Georges, Carlson, Keuren-Jensen. Study supervision: Nakaji, Eschbacher, Feuerstein, Anderson, Preul, Keuren-Jensen.

References


Manuscript submitted October 14, 2013. Accepted November 22, 2013. Please include this information when citing this paper: DOI: 10.3171/2013.11.FOCUS13478.

Address correspondence to: Peter Nakaji, M.D., c/o Neurosurgery, Barrow Neurological Institute, St. Joseph’s Hospital and Medical Center, 350 W. Thomas Rd., Phoenix, AZ 85013. email: neuropub@dignityhealth.org.